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Efforts to find a cure for the devastating inherited bliste-
ring disease, epidermolysis bullosa (EB), have received 
much attention in recent years. The extremely poor 
long-term prognosis of EB has motivated many patients 
and clinicians to pursue high-risk experimental thera-
pies (1–6). One such therapeutic strategy is allogeneic 
haematopoietic cell transplantation (HCT) in recessive 
dystrophic epidermolysis bullosa, generalized severe, 
(RDEB-gen-sev) patients (1), who completely or partially 
lack type VII collagen (Col7) at the dermo–epidermal 
junction (DEJ).
Based on encouraging results in mice (7, 8) and humans 
(1), we designed a study in the Netherlands. We aimed 
to treat 11 RDEB-gen-sev patients using a previously 
described HCT protocol (9, 10) (Fig. S11). 
Between May 2014 and October 2017, 2 RDEB-gen-
sev patients were enrolled and treated following the 
study protocol. Unfortunately, both patients died due to 
transplantation-related complications after 50 and 283 
days after cord blood transplantation (CBT), respectively. 
We wish to report detailed results of this trial which has 
now been prematurely closed.
CASE REPORTS
The first patient (#1; EB109-01) was a 13-year-old girl with 
an extensive RDEB-gen-sev phenotype due to homozygous 
mutation in intron 20 of COL7A1 gene (NM_000094.3); 
c.[2710+1G>A];[2710+1G>A] with no Col7 expression in im-
munofluorescence antigen mapping (IFM; monoclonal antibody 
LH7:2, Sigma-Aldrich, Poole, UK). Minimal toxicity was noticed 
with conditioning and the skin condition slightly improved with 
reduced blistering and inflammation. Unfortunately, the 4/6 cord 
blood graft (6/10 matched on high resolution molecular typing; 
NC/kg=6.4 × 107/kg) was rejected (bone marrow aspirate con-
firmed day +25, 85% patient chimerism) with the course being 
further complicated by very early cytomegalovirus reactivation 
(day +2), prolonged neutropaenia without autologous recovery, 
followed by multiple bacterial- and therapy-resistant aspergillus 
infections, resulting in her death (day +50). The study was put on 
hold and the treatment protocol was adjusted to improve safety 
by adding: cryopreservation of an autologous back-up graft (for 
rescue in case of non-engraftment), targeting the pre-HCT ATG 
to high exposure > 80 AU*d/l (while assuring low post-HCT 
exposure < 10 AU*d/l) to reduce the probability of donor-graft 
rejection and anti-fungal prophylaxis with liposomal amphotericin 
B instead of fluconazole.
The second child (#2; EB402-01), was an 8-month-old boy, with 
a homozygous large deletion starting in intron 12 and ending in 
exon 24 of the COL7A1 gene; c.[1637-240_3252del4061],[1637-
240_3252del4061] resulting in no Col7 expression on IFM (Fig. 
S21). At baseline, he had minimal cutaneous involvement, severe 
mucosal (oral and ocular) erosions and nail dystrophy (Fig. S21). 
The conditioning was well tolerated and he engrafted quickly (day 
+17) with a 5/6 unrelated cord blood unit (matched 7/10 on high-
resolution molecular typing; NC/kg = 15.1 × 107/kg). However, the 
treatment course was complicated with several transplantation-
related toxicities, requiring resuscitation and multiple intensive 
care admissions. These included refractory grade III skin graft 
vs. host disease (GvHD), acute oesophageal bleeding, gastric 
paresis, capillary leak syndrome, pneumothorax and severe re-
spiratory insufficiency. Several switches in immunosuppression 
were necessary due to medication-induced transplantation-related 
microangiopathy and kidney toxicity. Acute GvHD was controlled 
with 3 additional mesenchymal stromal cell infusions (outside 
the treatment protocol) and basiliximab. Gastroenteral GvHD 
was suspected, but never proven, despite extensive endoscopic 
evaluation. Similar to patient 1, patient 2 also developed cytome-
galovirus reactivation, even before transplant, which was treated 
pre-emptively. The load waxed and waned over the disease course, 
but was never higher than log3 IU/ml. He also had multiple 
bacterial infections, which were well-controlled. The respiratory 
problems, however, persisted and required ventilation (4 separate 
episodes) and oxygen support, leading to progressive decline in 
lung function and ultimately death (day +283). We are unable to 
fully explain whether all these complications were related to the 
immunological phenomena of a CBT or EB.
In addition to the multiple life-threatening complications in 
patient 2, there was clear lack of clinical or biological evidence 
of efficacy in ameliorating the EB disease course, despite >97% 
donor peripheral blood chimerism and 9 months’ follow-up. Mu-
cosal blistering flared up and persisted throughout the treatment 
period. Cutaneous blistering was seen during hospital admission, 
largely explained by iatrogenic trauma. The mini-skin rub test 
was persistently positive (day +180) (11). Neither Col7, nor its 
main constituent anchoring fibrils were detected at the various 
time-points, including post-mortem (day +283) (Fig. S21). Unfor-
tunately, we could not assess dermal chimerism (with X-Y FISH), 
as the donor and recipient were the same sex.
DISCUSSION
The first HCT trial in 2010, described treatment of 6 
RDEB-gen-sev patients, with transplantation-related 
mortality in one patient and clinical improvement in the 
remaining 5 patients, including presence of donor cells in 


























































(1). Later, in another HCT trial, 2 RDEB-gen-sev patients 
survived the treatment, showed dermal chimerism and ex-
hibited some short-lived clinical benefit; how ever, no Col7 
was re-instituted after HCT (12). A report from an inter-
national EB meeting in 2017 stated that no individual has 
been cured after HCT, but mortality rates have improved 
and several patients showed a marked reduction in blister 
formation with major improvement in quality of life (13).
Although, we also observed some temporary beneficial 
effects from the treatment in both of our patients, their 
dramatic course of treatment did bring to light many is-
sues. Firstly, could the clinical improvement observed 
after HCT, with or without Col7 expression or anchoring 
fibril formation (1, 12), be attributed to the wound-healing 
properties of immunosuppressive medications, parti-
cularly corticosteroids (14), used during HCT treatment 
protocols?
Secondly, it is important to understand whether haema-
topoietic stem cells (HSC) that migrated to the skin are 
capable of producing Col7 at the DEJ. It is well known 
that Col7 at the DEJ is contributed by both keratinocytes 
and fibroblasts. The differentiation capabilities of these 
migrated HSCs are not yet clearly understood, with some 
studies suggesting that HSCs might not be capable of 
trans-differentiation into keratinocytes, while others sug-
gest that the HSCs might convert into dermal fibroblasts, 
particularly at wound sites where remodelling is occurring, 
contributing to the reported increase in Col7 expression 
(1, 4, 5, 7, 15, 16).
Finally, the most important question that arises is what 
qualifies for success attributable to HCT in EB? Although, 
clinical improvement has been reported, it is difficult to 
speculate if such an effect is temporary, as the long-term 
benefit of haematological engraftment remains to be 
shown. If HCT promises mostly symptomatic alleviation 
with no or limited biological correction of disease, i.e. 
reconstitution of Col7 and/or anchoring fibrils, other safer 
therapeutic options should be considered. Taken together, 
our study team, in accordance with the safety monitoring 
board recommendation, suspended and subsequently 
closed the trial. HCT for severe forms of dystrophic EB 
remains a high-risk therapeutic option of undetermined 
clinical benefit.
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